Kyasanur Forest Disease (KFD), a tick-borne viral infection endemic to the Western Ghats, is set to get an improved indigenous vaccine. The Indian Council of Medical Research (ICMR), in collaboration with Indian Immunologicals Limited and the ICMR-National Institute of Virology, has advanced a two-dose adjuvanted inactivated vaccine. The doses are planned 28 days apart. The initiative was taken after a request from the Karnataka government, as KFD continues to affect parts of Karnataka, Tamil Nadu, Kerala, Goa and Maharashtra.
What is Kyasanur Forest Disease?
KFD is a regional infectious disease transmitted mainly through ticks. It is often associated with forested and adjoining areas of the Western Ghats. The disease can cause fever, headache, muscle pain and, in severe cases, haemorrhagic complications. It remains a public health concern in affected states due to recurring outbreaks.
Vaccine Development Progress
- The vaccine has been developed as a fully indigenous product.
- Animal challenge studies and toxicity studies have been completed.
- GLP-grade vaccine material has been manufactured.
- Phase I human clinical trial has begun after approval from the Central Drugs Standard Control Organisation (CDSCO).
Clinical Trial and Regulatory Path
If the Phase I trial shows safety and immunogenicity, further clinical trials will follow. The final approval will be sought from CDSCO after successful completion of the required stages. The vaccine is designed to strengthen India’s response to a difficult regional disease with limited preventive options.
Significance for Public Health
The project reflects India’s push for domestic vaccine development for neglected and region-specific diseases. It also marks cooperation between a national research body, a public-sector research institute and a private manufacturer. The effort may improve long-term prevention in vulnerable forest-dwelling and tribal populations exposed to KFD.
Last Modified: April 28, 2026